Sware is a tech-first company, transforming compliance in life sciences and supporting an industry-wide transition from an inefficient, manual approach to an automated, workflow-driven, data-centric solution. Sware delivers process automation and a single source of validation truth for customers who want ground-breaking results.
By driving the end-to-end validation process, Sware’s platform enables painless adoption of emerging technologies for healthcare, life sciences, and SaMD companies. With advanced technology and automation, Sware ensures consistency in compliance and keeps companies in a state of inspection readiness.
We have helped more than 275 healthcare and life sciences companies transition to the regulated cloud. With advanced technology and automation, Sware was founded by the same leaders who took Veeva Vault and the life sciences industry into the cloud. Today, we’re evolving to meet the needs of Validation 4.0 by instilling trust and quality in the new technologies of Pharma 4.0.
We are validation to Sware by.
By driving the end-to-end validation process, Sware’s platform enables painless adoption of emerging technologies for healthcare, life sciences, and SaMD companies. With advanced technology and automation, Sware ensures consistency in compliance and keeps companies in a state of inspection readiness.
We have helped more than 275 healthcare and life sciences companies transition to the regulated cloud. With advanced technology and automation, Sware was founded by the same leaders who took Veeva Vault and the life sciences industry into the cloud. Today, we’re evolving to meet the needs of Validation 4.0 by instilling trust and quality in the new technologies of Pharma 4.0.
We are validation to Sware by.
Location: United States, Massachusetts, Chelsea
Employees: 51-200
Total raised: $21M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | Right Side... | rightsidec... |
| 11.09.2024 | First Anal... | firstanaly... |
| 12.10.2022 | Insight Pa... | insightpar... |
| - | Jumpstart ... | jscap.co |
| - | New Stack ... | newstack.c... |
| 21.10.2022 | LRVHealth | lrvhealth.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.06.2024 | Series B | $6M | - |
| 09.02.2022 | Series A | $15M | Insight Pa... |
Mentions in press and media 11
| Date | Title | Description |
| 28.05.2025 | Future-Proofing GxP: Strategic Investments and Validation Best Practices for CDMOs Amid Emerging Health Authority Regulations, Upcoming Webinar Hosted by Xtalks | www.sware.com In this free webinar, gain insight into how regulatory bodies are transitioning validation guidelines to risk-based computer system assurance (CSA) and what this means for contract development and manufacturing organization (C... |
| 28.10.2024 | Process over Projects: Rethinking GxP System Validation in an Age of Rapid Change, Upcoming Webinar Hosted by Xtalks | www.sware.com During this informative session, participants will learn how treating validation as a core part of a quality management system (QMS) can significantly improve an organization's ability to manage validation risk and maintain co... |
| 09.10.2024 | Sware Appoints Bryan Ennis as Chief Quality Officer, Enhances Res_Q™ Platform for Life Sciences GxP Validation | Sware bolsters commitment to quality and innovation in life sciences software validation through strategic leadership appointment and advanced platform updates BOSTON, NJ, UNITED STATES, October 9, 2024 /EINPresswire.com/ -- Sware, the lead... |
| 09.09.2024 | Managing Compliance Risk in Life Sciences: How Can IT and Quality Teams Root it Out | www.sware.com In this free webinar, learn how information technology (IT) and quality teams in life sciences organizations can both protect and deliver exceptional value by developing a systematic way to assess and grade risk, strengthening... |
| 10.06.2024 | Sware: Life Sciences Software Validation Solution Company Raises $6 Million | Sware, a provider of the most complete software validation solution for innovative life sciences companies, announced that it raised $6 million in Series B funding, bringing its total raised since inception to $26 million. This funding roun... |
| 07.06.2024 | Sware Revolutionizes Software Validation for Life Sciences Industry | A deep dive into how Sware's innovative platform is reshaping the validation process for pharmaceutical, medical device, and biotechnology companies, eliminating validation debt and streamlining operations. In a world where software updates... |
| 07.06.2024 | Sware Raises $6M in Series B Funding | Sware, a Boston, MA-based provider of a software validation solution for innovative life sciences companies, raised $6M in Series B funding. The round was led by First Analysis, with participation from existing investors including LRVHealth... |
| 07.06.2024 | First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing | First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and devel... |
| 06.06.2024 | Sware, a software validation platform for the life sciences industry, raises $6M | The company automates the validation process that the FDA requires every time software is updated Every time software that pharma, medical device and biotech companies use for development and manufacturing gets updated, the FDA requires it ... |
| 06.06.2024 | Sware Secures $6M to Help Life Sciences Eliminate Validation Debt | What You Should Know – Sware has secured $6 million in Series B funding to enhance its software validation solution for life sciences companies. – The new funding will support research and development, AI-driven capabilities, and expansion ... |
Show more